PDF) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study

PDF) Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular AMD Patients: A “Real World” Analysis in 49,485 Eyes

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan

PDF) Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration – results from the randomized, phase IIIb OCTAVE study

PDF) Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan

Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study, Health and Quality of Life Outcomes

PDF) Ranibizumab for the treatment of wet AMD: A summary of real-world studies

Retinal Physician - Managing Treatment Resistance in Neovascular Age-related Macular Degeneration

Frontiers Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model

PDF) End of Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration

Frontiers Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model

Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration

Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study, BMC Ophthalmology